| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,933,736 | -1,395,817 |
| Depreciation expense | 61,551 | 38,403 |
| Stock-based compensation | 62,459 | 42,544 |
| Provision for credit losses | 41,401 | 12,525 |
| Provision for inventory obsolescence | 9,119 | 9,119 |
| Vendor expense settled in shares of common stock | 33,000 | 15,000 |
| Amortization of operating lease right of use assets | 52,978 | 34,905 |
| Accounts receivable, net | 445,448 | 84,760 |
| Inventory, net | 60,304 | 24,493 |
| Prepaid expenses and other current assets | -65,208 | -108,515 |
| Accounts payable | 272,469 | 93,694 |
| Accrued expenses | 98,492 | 22,154 |
| Deferred revenue | 1,350,000 | 1,425,000 |
| Operating lease liabilities | -49,514 | -32,598 |
| Net cash used in operating activities | -442,325 | 264,191 |
| Purchases of property and equipment | 231,551 | 231,551 |
| Net cash used in investing activities | -231,551 | -231,551 |
| Net proceeds from issuance of common stock | 791,418 | 0 |
| Net proceeds from option exercises | 113,541 | - |
| Net proceeds from warrant exercise | 0 | 0 |
| Net cash provided by financing activities | 904,959 | 0 |
| Net increase (decrease) in cash | 231,083 | 32,640 |
| Cash and cash equivalents at beginning of period | 283,714 | - |
| Cash and cash equivalents at end of period | 514,797 | - |
Nuo Therapeutics, Inc. (AURX)
Nuo Therapeutics, Inc. (AURX)